Breaking News

Assign Clinical Research Joins Celerion

January 14, 2016

Expands global presence and capabilities for complex early clinical studies

Assign Clinical Research, headquartered in Vienna, Austria, has joined Celerion, expanding its global presence and capabilities for complex early clinical studies. Assign conducts early stage clinical studies, as well as specialized later stage studies, across a broad range of therapeutic areas with a particular focus in oncology, vaccines, cancer immunotherapy, personalized medicine and autoimmune disorders. They specialize in difficult to recruit studies through relationships with study centers located across 30 countries.
  
“Assign perfectly complements Celerion’s services in early clinical development,” said Susan Thornton Ph.D., president and chief executive officer at Celerion. “I am excited to bring two industry leaders together to provide our clients with a highly specialized suite of services which strengthens our competencies in Applied Translational Medicine. The talent and scientific expertise at Assign combined with that of Celerion deepens our position as the global leader in early clinical research.” 
 
“There is a strong cultural fit with Assign and Celerion,” said Klaus Fischer Ph.D., chief executive officer at Assign. “Both companies are committed to delivering on our clients’ ever-evolving needs in the conduct of complex clinical studies. I look forward to joining the Celerion team to integrate our services and offer clients access to the largest and the most comprehensive global early stage clinical research organization.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research